{"id":"placebo-to-fosfomycin","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Vaginitis"}]},"_chembl":{"chemblId":"CHEMBL1757","moleculeType":"Small molecule","molecularWeight":"138.06"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fosfomycin irreversibly inhibits the enzyme MurA (UDP-N-acetylglucosamine enolpyruvyl transferase), which catalyzes an early step in peptidoglycan biosynthesis. This disruption of cell wall formation leads to bacterial cell death. The drug is effective against both gram-positive and gram-negative bacteria, including many resistant strains.","oneSentence":"Fosfomycin is a broad-spectrum antibiotic that inhibits bacterial cell wall synthesis by blocking peptidoglycan cross-linking.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:26.170Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated urinary tract infections"},{"name":"Acute cystitis"},{"name":"Complicated urinary tract infections (in combination therapy)"}]},"trialDetails":[{"nctId":"NCT07063095","phase":"PHASE3","title":"A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections","status":"RECRUITING","sponsor":"Angela HUTTNER","startDate":"2025-08-25","conditions":"Gram Negative Infections, Sepsis and Septic Shock","enrollment":100},{"nctId":"NCT03151603","phase":"PHASE4","title":"Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial","status":"COMPLETED","sponsor":"University Medical Center Goettingen","startDate":"2017-05-03","conditions":"Urinary Tract Infections","enrollment":398},{"nctId":"NCT03176563","phase":"","title":"Observational Follow-up Study of REGATTA","status":"COMPLETED","sponsor":"University Medical Center Goettingen","startDate":"2017-05-03","conditions":"Urinary Tract Infections","enrollment":398},{"nctId":"NCT03235947","phase":"PHASE4","title":"Perioperative Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2016-09-07","conditions":"Urinary Tract Infection, Asymptomatic Bacteriuria","enrollment":82},{"nctId":"NCT02639520","phase":"PHASE3","title":"Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs","status":"COMPLETED","sponsor":"Bionorica SE","startDate":"2015-12","conditions":"Urinary Tract Infection","enrollment":659},{"nctId":"NCT01969799","phase":"PHASE2","title":"Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia","status":"COMPLETED","sponsor":"Cardeas Pharma","startDate":"2013-12","conditions":"Pneumonia, Bacterial","enrollment":143},{"nctId":"NCT01931592","phase":"PHASE2, PHASE3","title":"Controling Intestinal Colonization With Extended Spectrum ß-Lactamase Producing Enterobacteriaceae ESBL-E","status":"TERMINATED","sponsor":"Maria J.G.T. Vehreschild","startDate":"2014-01","conditions":"Cancer","enrollment":29},{"nctId":"NCT02218359","phase":"PHASE2","title":"Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative and / or Gram-positive Bacterial Colonization","status":"WITHDRAWN","sponsor":"Cardeas Pharma","startDate":"2014-10","conditions":"Pneumonia, Bacterial","enrollment":""},{"nctId":"NCT01488955","phase":"PHASE4","title":"Immediate vs. Conditional Use of Antibiotics in Uncomplicated Urinary Tract Infection (UTI) - ICUTI","status":"COMPLETED","sponsor":"Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH","startDate":"2012-02","conditions":"Urinary Tract Infection","enrollment":494}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo to Fosfomycin","genericName":"Placebo to Fosfomycin","companyName":"University Medical Center Goettingen","companyId":"university-medical-center-goettingen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fosfomycin is a broad-spectrum antibiotic that inhibits bacterial cell wall synthesis by blocking peptidoglycan cross-linking. Used for Uncomplicated urinary tract infections, Acute cystitis, Complicated urinary tract infections (in combination therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}